CLINICAL Treating actinic keratoses PRACTICE with imiquimod
• There are many options for managing actinic
keratoses. Percentage complete clearance of lesions
with cryotherapy is in the order of 80%, topical
imiquimod 70% and 5 fluorouracil 50%.2–5
• Some patients will find some of the options
more tolerable than others. Consider trying
alternative approaches for patients with
the treatment very uncomfortable and can
being treated on each visit. He develops
lesions faster than lesions are treated. Mr KC now presents with numerous hyperkeratotic lesions on his face (Figure 1). Biopsies were taken of the clinically most suspicious actinic lesions. This is done to identify which, if any, lesions are SCCs. (These are surgically excised.) Numerous actinic keratoses still covered most of his face including most of his left forehead.
He was keen to try imiquimod for his residual actinic keratoses. We divided his face up into regions about the size of a playing card. In turn he treated each region with an application of imiquimod three times per
Figure 1. The patient’s face is covered with actinic lesions,
week for 6 weeks. This is the recommended protocol
especially the forehead. The lesions marked with pen are all
SCCs and were surgically excised. There was further
for usage of imiquimod for actinic keratoses.
SCC on the right eyebrow, also surgically excised
The final section of face skin to be treated was the right forehead. Mid treatment the area was red and angry looking, as part of the expected immune response induced by the imiquimod1 (Figure 2). This erythema and irritation was never disturbing to the patient. If imiquimod causes excess irritation, the clinician can advise the patient to leave out a dose or two. Upon completion Mr KC had no apparent actinic lesions on his face or forehead (Figure 3). Summary of important points • Treat malignant lesions before benign lesions. It is
the SCCs that can metastasise and potential y kil
Figure 2. The skin is typically red and angry looking for the
patients. Once the SCCs are excised, the focus can
duration of imiquimod management of actinic keratoses.
Imiquimod was only commenced following all surgical excisions
Reprinted from Australian Family PhysicianVol. 36, No. 5, May 2007341
CLINICAL PRACTICE Treating actinic keratoses with imiquimod
Numerous actinic keratoses There are five characters of an actinic keratosis that should be considered upon
examination: • Hyperkeratosis: to what extent does the keratosis extend above the skin
• Full thickness: when the lesion is manipulated with your fingers upon
examination, does it appear to be deeply into the skin or very much a surface
• Surrounding induration: is there enhanced thickness in the tissue adjacent to
• Surrounding erythema: is the immediate adjacent skin clearly redder than the
• Tenderness: is the lesion causing the patient any degree of discomfort?
Does the patient withdraw when you touch one or more lesions in the field of
The more of these characteristics an individual lesion has, the more likely the
lesion is to be a malignant SCC rather than a premalignant lesion. In patients
with large numbers of keratoses, consider biopsy of the lesions that have the
greatest number of these features. Regardless of the number of keratoses a patient suffers, lesions with three or
more of these five features should be biopsied. If any lesion demonstrating several of these features does not respond to
cryotherapy, biopsy rather than treating repeatedly with cryotherapy or
1. Vidal D. Topical imiquimod: mechanism of action
and clinical applications. Mini Rev Med Chem 2006;6:499–503.
2. Tutrone WD, Saini R, Caglar S, Weinberg JM, Crespo J.
Topical therapy for actinic keratoses, I: 5-fluorouracil and imiquimod. Cutis 2003;71:365–70.
3. Del Rosso JQ. New and emerging topical approaches for
actinic keratoses. Cutis 2003;72:273–6, 279.
4. Falagas ME, Angelousi AG, Peppas G. Imiquimod for
the treatment of actinic keratosis: a meta-analysis of randomised control ed trials. J Am Acad Dermatol 2006;55:537–8.
5. Gupta AK, Davey V, McPhail H. Evaluation of the
Figure 3. Following treatment there is no apparent
effectiveness of imiquimod and 5-fluorouracil for the
treatment of actinic keratosis: Critical review and meta-analysis of efficacy studies. J Cutan Med Surg 2005;9:209–14.
6. Dixon AJ. Multiple superficial basal cel carcinomata:
topical imiquimod versus curette and cryotherapy. Aust
• Imiquimod is approved in Australia for
field actinic keratoses only on the face and forehead. The patient applies a ful sachet three times per week to an area of skin equivalent to the forehead on one side. One sachet wil cover a field about this size. Once one region has completed management, a new region may be commenced.
Conflict of interest: none declared. CORRESPONDENCE email: [email protected] 342 Reprinted from Australian Family PhysicianVol. 36, No. 5, May 2007
Import von Arzneimitteln durch Privatpersonen Internet: www.ag.llv.li Postfach 684 | 9490 Vaduz | Liechtenstein | T + 423 236 73 25 | F + 236 73 50 |Merkblatt_Privatpersonen_111212 Was gilt als Arzneimittel1? Beispiele für importierte Arzneimittel: Tabletten zur Erektionsförderung: Viagra, Cialis Tabletten zum Abnehmen: Xenical, Alli Präparate zum Muskelaufbau: Anabolika Nasenspra
Parte II Formación del contrato 1) Toda declaración u otro acto del destinatario que indique asentimiento a una oferta constituirá aceptación. El silencio o la inacción, por sí solos, no constituirán 2) La aceptación de la oferta surtirá efecto en el momento en que la indicación de asentimiento llegue al oferente. La aceptación no surtirá efecto si la indicación de asentimient